Tate & Lyle reaches sweetener milestone as Tate & Lyle stock costs EUR 6.73

Published on 10/20/2026 at 13:00 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

BioHarvest sweetener progress came on October 8, 2026. Tate & Lyle stock costs EUR 6.73 on October 20, 2026, with GBP 2.0 billion revenue in fiscal year 2026.

Sweetener progress and annual results

Tate & Lyle and BioHarvest reported a sweetener development milestone on October 8, 2026.
Fiscal year 2026 revenue rose 15.55 percent to GBP 2,006 million from GBP 1,736 million.
Tate & Lyle stock trades at EUR 6.73 at 12:49 p.m. CEST at Lang & Schwarz on October 20, 2026.

Aquarellmalerei der Londoner Skyline mit Themse und Brücken — Tate & Lyle PLC (GB0008707753) mit Hauptsitz in London, dargestellt als sanftes Aquarell der Themse-Skyline, Illustration mit AI erstellt.

Tate & Lyle (GB00BP92CJ43) had reached a development milestone with BioHarvest on October 8, 2026, while its stock was at EUR 6.73 at Lang & Schwarz on October 20, 2026. The project targets a next-generation sweetener through BioHarvest's Botanical Synthesis platform, according to Tate & Lyle.

Sweetener platform reaches a milestone

The October 8 announcement said BioHarvest's platform had demonstrated its ability to produce the targeted sweetening solution. Tate & Lyle and BioHarvest said development activities were continuing in line with expectations, making the update an early-stage product development signal rather than a commercial revenue announcement.

The project builds on an expanded collaboration announced in May 2026. Its potential value lies in adding another route to ingredient development that could support sugar reduction and supply reliability, although the release did not disclose a commercial launch date or financial contribution.

What do the annual figures show?

Tate & Lyle's fiscal year 2026 revenue was GBP 2,006 million, up 15.55 percent from GBP 1,736 million in fiscal year 2025, according to Reuters. Operating profit reached GBP 241 million in fiscal year 2026, compared with GBP 251 million in fiscal year 2025.

Net income also fell to GBP 97 million from GBP 143 million over the same periods, a decline of 32.17 percent. That contrast gives the sweetener program strategic relevance, but the current earnings picture still depends on turning product development and integration work into profitable growth.

Next reporting date approaches

The next earnings release is listed for November 4, 2026, by MarketScreener. That report should provide the next quantified test of revenue, profit and integration progress after the fiscal year 2026 figures.

Stock price and investor context

Tate & Lyle's primary listing is on the London Stock Exchange, where the share was last quoted at GBp 563.50 on October 20, 2026. Its 52-week range was GBp 319.40 to GBp 650.00, and its market capitalization was GBP 2.5 billion on the same date.

The company operates in packaged foods and supplies specialized ingredients for food, beverage and industrial customers. For investors, the key tension is visible in the figures: fiscal year 2026 revenue increased from GBP 1,736 million to GBP 2,006 million, while net income decreased from GBP 143 million to GBP 97 million.

Tate & Lyle was trading at EUR 6.73 at Lang & Schwarz on October 20, 2026 at 12:49 p.m. CEST.

The further course of trading is shown by the continuously updated real-time quote of Tate & Lyle stock.